2ELISABETH B,JOHN L W,NOELLA G,et al . Antiinflammatory Activities of a New Series of Selective Phosphodiesterse 4 Inhibitors Derived from 9-Benzylad-enine[J]. J Pharmacol Exp Ther, 2000, 292 (2) : 647-653.
3VITTIORIO D P, MARIA P G. Phosphodiesterase 4 Inhibitors, Structurally Unrelated to Rolipram, as Promising Agents for the Treatment of Asthma and Other Pathologies[J]. Eur J Med Chem, 2000,35 (5) :463-480.
4BODOR N.Novel Apprlaches to the Desing of Safer Drugs:Soft Drugs and Site-specific Chemical Delivery Systems[A].BERNARD T.In Aduvnces in Drug Research(Vol 13)[C].New York:Academic Press,1984.255-331.
5BODOR N,WOODS R,RAPER C,et al.Soft Drugs:3-a New Class of Anticholinergic Aents[J].J Med Chem,1980,23(3):474-480.
6仇缀百.药物设计学[M].北京:高等教育出版社,2000..
7Boder N. Novel approaches to the design of safer drugs:soft drags and site - specific chemical delivery system[A]. Bernard T. Advances in Drug Research (Vol 13)[ C ]. New York : Academic Press. , 1984. 255 - 331.
8Brouillette G, Kawamura M, Kumar GN et al. Soft drugs.21. Design and evaluation of soft analogs of propantheline[J].J Pharm Sci,1996, 85(6): 619-623.
9Bodor N,Buchwald P. Designing safer(soft) drugs by avoiding the formation of toxic and oxidative metabolites [ J ].Methods Mol Biol,2002,186:301 - 312.
10Bodor N. Recent advances in retrometabolic drug design and targeting approaches [ J ]. Pharmaxie, 2000,55 ( 3 ) :163 - 166.
